Gracell Biotechnologies Inc
GRCL.OQ- Latest Trade
- trading higher3.79USD
- Change
- 0.13
- % Change
3.55%Positive
- As of Aug 8 2022. Values delayed up to 15 minutes
- Day Range
- 3.58 - 3.79
- 52-Week Range
- 1.68 - 15.00
- Previous Close
- 3.66
- Open
- 3.66
- Volume
- 5,652.00
- 3 Month Average Trading Volume
- 2.54
- Shares Out (Mil)
- 337.50
- Market Cap
- 262.01
- Forward P/E
- -12.03
- Dividend Yield
- -99,999.99
Key Statistics
1.6 mean rating - 5 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 4,839.78
- Price To Book (Quarterly)
- 0.87
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 5.76
- Long Term Debt/Equity (Quarterly)
- 2.82
- Return On Investment (TTM)
- -34.36
- Return On Equity (TTM)
- -32.06
2021 (millions USD)
About Gracell Biotechnologies Inc (GRCL.OQ)
Company Information
Gracell Biotechnologies Inc is a China-based clinical-stage biopharmaceutical company focused on discovering and developing cell therapies for the treatment of cancers. The Company is primarily focused on disrupting conventional approaches to chimeric antigen receptor (CAR) thymus (T) cell therapies by leveraging its technology platforms FasTCAR and TruUCAR. With FasTCAR, the Company is able to deliver younger, less exhausted T cells for autologous cell therapies with enhanced activities and next-day manufacturing. With TruUCAR, the Company is able derive T cells from non-human leukocyte antigen (HLA)-matched healthy donors to generate allogeneic CAR-T cell therapies. The Company is levering its technology platform to develop various drug candidates, including GC012F, GC019F, GC007F, GC027 and GC007g.
Address
Building 3 418 Guilin Road, Xuhui DistrictSHANGHAI, SHA
200030
China
Industry
Business Services
Executive Leadership
- Wei Cao
- Chairman of the Board, Chief Executive Officer, Founder
- Yili Xie
- Chief Financial Officer
- Yajin Ni
- Chief Technology Officer
- Martina Sersch
- Chief Medical Officer
- Guowei Wang
- Director
- Wendy Hayes
- Independent Director
- Kin Ping Lee
- Independent Director
- Guotong Xu
- Independent Director
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,772.90 | -- |
| Copper | 656.05 | 0.03%Positive |
| Brent Crude Oil | 95.18 | 0.27%Positive |
| CBOT Soybeans | 1,614.75 | -- |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,145.19 | 0.16%Negative |
| Euro STOXX 50 | 3,725.39 | -- |
| FTSE 100 | 7,439.74 | 0.11%Negative |
| Nikkei 225 | 28,252.71 | 0.27%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes